Skip to main content

Table 2 Results of base case analysis

From: Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

  Vaborem BAT Difference Percentage change
Costs (€)  
Total Costs 29,750.85 26,202.28 3548.57 13.5%
 Pharmacological treatment 2301.49 1485.23 816.26 55.0%
 Admission 3048.04 3048.04 0.00 0.0%
 Therapeutic failure 1841.64 3324.40 − 1482.76 −44.6%
 Chronic RRT 129.49 873.10 − 743.61 − 85.2%
 Long-term care 22,430.18 17,471.51 4958.68 28.4%
Clinical Effectiveness  
Total QALY 1.786 1.403 0.384 27.4%
 Nephrotoxicity-free hospitalisation 0.033 0.031 0.002 7.2%
 Hospitalisation with nephrotoxicity 0.002 0.013 −0.012 − 88.3%
 Acute RRT 0.000 0.002 −0.002 −85.2%
 Chronic RRT (after 90 days) 0.002 0.013 −0.011 −85.2%
 After Hospital discharge 1.749 1.343 0.406 30.3%
Total LYs 2.253 1.778 0.475 26.7%
  1. BAT: best available therapy; LY: life years; QALY: quality assisted life years; RRT: renal replacement therapy